This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

Predicting response in treatment-naïve RA: Harnessing the power of multi-modal analysis

arthritis
Credit: Pixabay/CC0 Public Domain

New work presented at the 2024 congress of EULAR—The European Alliance of Associations for Rheumatology—assesses the power of multi-modal analysis of synovial tissue inflammation in treatment-naïve patients with rheumatoid arthritis (RA). The hope is to identify predictive biomarkers for treatment response.

The synovial inflammation seen in RA shows a high degree of heterogeneity—which may be a factor in people's variable response to treatments. We also know that distinct synovial tissue macrophage subsets regulate inflammation and remission in . The potential of high-throughput analyses has been shown, and these technologies can help dissect disease heterogeneity and identify novel biomarkers that could be used in prognosis.

To explore this further, 373 treatment-naïve RA patients were enrolled and given an ultrasound-guided synovial tissue biopsy. The synovitis degree and synovial pathotype were then determined for each individual. A subset of 45 samples was used for synovial tissue macrophage phenotyping and profiling in order to measure the abundance of distinct macrophage populations. Moreover, the transcriptomic profile of CD68pos cells in distinct regions of interest within the synovial tissue was determined using spatial technology. After study entry, patients were managed with a treat-to-target strategy.

The findings showed that those patients who reached disease remission at 6 months had lower Krenn Synovitis Score (KSS) at baseline compared to people who did not achieve this outcome. People who had been stratified based on synovial pathotype as lympho-myeloid or diffuse-myeloid pathotype had a lower response to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) compared to people with a pauci-immune pathotype. However, further analysis suggested that at an individual level, baseline KSS has limited capacity to distinguish between responders and non-responders, which highlights the need for multi-modal tissue deconvolution.

Flow cytometry analysis revealed that those with lympho-myeloid or diffuse-myeloid pathotypes showed comparable enrichment of two distinct synovial tissue macrophage populations (MerTKposCD206pos and MerTKnegCD206neg), while patients with the pauci-immune pathotype showed a predominance of MerTKposCD206pos. The enrichment of MerTKposCD206pos synovial tissue macrophages was also higher in people who achieved remission at 6 months. Notably, enrichment of these MerTKpos synovial tissue macrophages greater than 44.3% from baseline was shown to be an independent factor associated with achieving remission at 6 months.

Digital spatial profiling of synovial tissue biopsies revealed differential gene networks activating the macrophages in distinct tissue locations. This method was also able to identify transcriptomic signatures of synovial tissue macrophages in the lining and sublining location that were associated with response to csDMARD. Integration of sequencing and transcriptomic data resulted in the group being able to map synovial tissue macrophage clusters and stratify them based on treatment response.

Such multi-modal analysis of synovitis could enable differentiation of treatment-naïve RA patients at their first medical evaluation, and the data strongly support the predictive value as a patient-based decision test tool.

More information: S. Alivernini et al, OP0062 Multi-modal analysis of synovial tissue macrophages informs on treatment response in naive to treatment Rheumatoid Arthritis, Scientific Abstracts (2024). DOI: 10.1136/annrheumdis-2024-eular.2383

Provided by European Alliance of Associations for Rheumatology (EULAR)
Citation: Predicting response in treatment-naïve RA: Harnessing the power of multi-modal analysis (2024, June 12) retrieved 21 June 2024 from https://medicalxpress.com/news/2024-06-response-treatment-nave-ra-harnessing.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Obesity associated with higher degree of synovitis in rheumatoid arthritis patients

 shares

Feedback to editors